Funding for this research was provided by:
National Cancer Institute (CA096297/CA096300)
National Institute on Minority Health and Health Disparities (2U54MD007587)
Received: 4 December 2019
Accepted: 26 January 2020
First Online: 24 February 2020
Ethics approval and consent to participate
: The research protocol was approved by the Institutional Review Board of the UPR Medical Sciences Campus (approval number A2210515).
: Not Applicable.
: MCC is advisor of EXACT Sciences and BeiGene Pharmaceuticals. Content related to her advisory roles is not related to the topic of the manuscript.